Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) (PAR-25-055)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Centers on the Demography and Economics of Aging, Including Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (D&E Centers) (P30 Clinical Trial Optional) (RFA-AG-25-007)

Sponsor: National Institute on Aging

Due Date: Letter of Intent due October 1, 2024. Application due November 01, 2024.

Centers on the Demography and Economics of Aging and Alzheimers Disease and Alzheimers Disease-Related Dementias Coordinating Center (U24 Clinical Trial Optional) (RFA-AG-25-008)

Sponsor: National Institute on Aging

Due Date: Letter of Intent due October 1, 2024. Application due November 01, 2024.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) (PAR-24-294)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) (PAR-25-050)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Notice of Special Interest (NOSI): The Role of the Immune System in Aging Brain and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (NOT-AG-24-010)

Sponsor: National Institute on Aging, National Institute of Allergy and Infectious Diseases

Award: This initiative relates to the following notices of funding opportunities (NOFOs): PAR-22-093 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional); PAR-22-094 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional).

Due Date: This notice applies to due dates on or after November 12, 2024 and subsequent receipt dates through December 31, 2027.

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) (PA-25-080)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-24-293)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) (RFA-NS-25-018)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (RFA-NS-25-024)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Application due January 24, 2025. Letter of intent due 30 days prior to application.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-25-051)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) (RFA-MH-26-120)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) (RFA-NS-25-017)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Coordinating Center to Support Consortium for Neuroscience AD and ADRD Research in Low- and Middle-Income Countries (U24 Clinical Trial Not Allowed) (RFA-AG-25-014)

Sponsor: National Institute on Aging

Award: Application budgets need to reflect the actual needs of the proposed project and must be limited to $350K in direct costs for year 1, $500k in direct costs for years 2 - 5. The maximum project period is 5 years.

Due Date: Letter of Intent due October 13, 2024. Application due November 13, 2024.

Notice of Special Interest (NOSI): Administrative Supplement Program to Add Fluid-based Biomarkers and APOE Genotyping to NINDS ADRD Human Subjects Research Grants (NOT-NS-24-135)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: Only existing awardees of NINDS AD/ADRD focused grants are eligible to apply. Individual requests can be no more than $150,000 in direct costs. Requests may be for one year of support only and the proposed project period must be within the project period of the parent award.

Due Date: November 11, 2024.